Instead, agents that disrupt the PGF/FLT1/AKT pathway, such as the pan-VEGFR inhibitor axitinib, are more likely to be effective at re-sensitizing PARPi-resistant breast cancers to PARPi. This evidence concerns the gene KDR and breast carcinoma.